Prior authorization denial rates for GLP-1 obesity prescriptions have been high, and industry reporting through 2024 put them well above half of requests in some plans
More consistent appetite suppression: Stable blood levels produce more consistent appetite reduction
Whats Happening Chemically When you exercise, your body undergoes a cascade of beneficial changes that counteract the effects of discontinuing GLP-1 medications
In cases of significant nausea, pharmacologic interventions such as prochlorperazine may be used as needed and are preferred over ondansetron
Key players driving the GLP-1 market include Novo Nordisk, Eli Lilly, Pfizer, AstraZeneca, Roche, Sanofi, Boehringer Ingelheim, and Tonghua Dongbao Pharmaceutical
They identified gastrointestinal (GI) issues, particularly vomiting and nausea, as the most common side effects for most GLP-1 RAs, while headache and joint pain were most frequently discussed in posts about tirzepatide